40 Questions Answered
by Clinical Evidence

Generic semaglutide in India (Noveltreat by Sun Pharma and Obeda by Biocon) costs approximately ₹3,000–₹6,000 per monthly dose at the starting dose of 0.25 mg/week, rising to approximately ₹8,000–₹15,000 at the maintenance dose of 1–2.4 mg/week depending on brand and pharmacy. Prices are significantly lower than Wegovy in Western markets. Costs vary — confirm with your pharmacist.

As of 2026, most Indian health insurance policies do not cover semaglutide for weight management. Coverage for the diabetes indication (Ozempic) varies by policy. Some corporate health plans include GLP-1 as part of metabolic health benefits. Check your policy documents or contact your insurer directly.

All four contain semaglutide. Ozempic (1 mg/week, Novo Nordisk) is approved for type 2 diabetes. Wegovy (2.4 mg/week, Novo Nordisk) is the obesity dose, available in Western markets. Noveltreat (Sun Pharma) and Obeda (Biocon) are Indian biosimilar versions approved for chronic weight management at comparable doses. Discuss which is right for you with a doctor.

Yes. Semaglutide is classified as a Schedule H drug in India and requires a valid prescription from a registered medical practitioner. It cannot legally be purchased over the counter. Self-medication with semaglutide is dangerous and illegal. A qualified doctor must assess your full medical history before prescribing.

Semaglutide is available at licensed pharmacies across India with a valid prescription. It is available through major pharmacy chains and online pharmacies that require prescription verification. Some hospitals dispense it directly. Do not purchase from unverified online sources — counterfeit GLP-1 products have been reported globally.

Biocon (Obeda) and Sun Pharma (Noveltreat) both manufacture Indian semaglutide biosimilars. Prices vary by dose and pharmacy. Both are CDSCO-approved. Compare prices at licensed pharmacies — do not compare with imported Ozempic or Wegovy, which have different dose strengths and pricing.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These affect 30–44% of users in STEP trials and are most prominent during dose escalation, typically improving over 4–8 weeks. Starting at a low dose (0.25 mg/week) and escalating slowly reduces severity. See safety data →

Absolute contraindications include personal or family history of medullary thyroid carcinoma or MEN2 syndrome, current or prior pancreatitis, and pregnancy or breastfeeding. Relative cautions include severe kidney disease, active gallbladder disease, and history of eating disorders. See contraindication evidence →

Semaglutide is contraindicated only in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). For other thyroid conditions such as hypothyroidism or Hashimoto's, semaglutide is generally not contraindicated, but you must discuss your full thyroid history with your prescribing doctor.

Emerging evidence supports GLP-1 use in women with PCOS and insulin resistance. Semaglutide reduces weight, improves insulin sensitivity, and may improve menstrual regularity. It is not contraindicated in PCOS. However, it must not be used during pregnancy — women with PCOS who may become pregnant should use reliable contraception. See PCOS evidence →

Yes. Semaglutide is commonly prescribed alongside metformin for type 2 diabetes — the ADA Standards of Care 2026 list GLP-1 as a preferred add-on to metformin for patients with obesity. Combining the two does not significantly increase hypoglycaemia risk since neither causes hypoglycaemia alone. Your doctor should review your full medication list. See diabetes evidence →

Clinical trials consistently show weight regain after stopping semaglutide. The STEP 4 trial found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year, while those who continued maintained their weight loss. Semaglutide treats obesity as a chronic condition — it is not a short-course treatment.

Weight loss from any intervention includes some muscle mass loss, typically 25–40% of total weight lost. Semaglutide is no exception. Resistance training and adequate protein intake (1.2–1.6 g/kg body weight) significantly reduce muscle loss during treatment. The cardiovascular and metabolic benefits of fat loss outweigh muscle loss concerns in most patients.

Yes. EASO 2025 guidelines specifically recommend GLP-1 receptor agonists for patients with obesity-related metabolic-associated steatohepatitis (MASH/NAFLD). Clinical studies show semaglutide reduces hepatic fat content and liver inflammation. Fatty liver disease is not a contraindication — it is a qualifying comorbidity that strengthens the case for treatment. See fatty liver evidence →

Pancreatitis is a known risk and a contraindication if you have a history of it. Current or prior pancreatitis is an absolute contraindication to semaglutide. In clinical trials, acute pancreatitis occurred at a low rate (less than 1%) but significantly more than placebo. Stop taking semaglutide immediately and seek medical care if you experience severe, persistent abdominal pain. See safety data →

In rodent studies, GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumours. This has not been observed in human clinical trials to date, including the 5-year SELECT trial. However, as a precaution, semaglutide is contraindicated in anyone with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. The absolute risk in humans without these risk factors appears very low based on current evidence.

The GLP-1 Check triage tool is a free, anonymous 5-step questionnaire that checks your biometrics (BMI, waist circumference) and health history against Indian clinical guidelines to generate a GLP-1 Readiness Score from 0–100, classified as Green, Amber, or Red. It takes under 3 minutes and requires no login.

No. The GLP-1 Check triage result is an informational screening tool, not a medical diagnosis or prescription. It cannot replace a clinical consultation with a qualified doctor who can review your complete medical history, current medications, and lab results. Always consult a physician before starting any treatment.

The score starts at 50 and adjusts based on BMI using Indian cut-offs (≥27.5 adds 20 points), waist-to-height ratio for abdominal obesity, presence of qualifying comorbidities (type 2 diabetes +20, cardiovascular disease +15, prediabetes +12), and soft cautions. Hard contraindications immediately produce a Red result regardless of score. See the clinical evidence →

A Green result (score ≥65/100) means your profile is broadly consistent with published eligibility criteria for GLP-1 therapy in India. It does not guarantee that semaglutide is right for you — a doctor must still review your complete medical history, current medications, and run blood tests before any prescription can be issued.

An Amber result (score 40–64/100) means your profile has some indicators worth discussing with a doctor, but eligibility is not clear-cut based on self-reported inputs alone. A clinical consultation, possibly with blood tests, will clarify whether GLP-1 therapy is appropriate for your specific situation.

A Red result (score below 40, or any hard contraindication present) means one or more factors in your self-reported inputs suggest GLP-1 therapy may not be appropriate at this time. This does not mean you have no treatment options — your doctor can discuss alternative weight management strategies suited to your profile.

Your triage inputs are stored anonymously using a random session ID — no name, email, or phone is linked to your assessment unless you voluntarily provide it via the lead capture form. Your data is never sold to third parties. If you submit your phone number, a specialist may contact you on WhatsApp regarding your result only.

The scoring logic is derived from ESI India obesity guidelines, CDSCO approval criteria, ICMR-INDIAB waist circumference data, ADA Standards of Care 2026, EASO 2025 guidelines, the STEP trial programme, and the SELECT trial. All sources are publicly disclosed in the Evidence Library →

GLP-1 (glucagon-like peptide-1) is a hormone secreted after eating that stimulates insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite by acting on brain receptors. GLP-1 receptor agonists like semaglutide mimic this hormone at higher, sustained concentrations, producing significant weight loss and glycaemic control beyond what natural GLP-1 achieves.

In the STEP 1 trial (participants without diabetes), once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight over 68 weeks, versus 2.4% with placebo. About 1 in 3 participants lost more than 20% of their body weight. Results vary — lifestyle factors, adherence, and individual biology all influence outcomes. See STEP trial data →

Obesity is a chronic disease. Clinical evidence shows that stopping semaglutide leads to substantial weight regain (STEP 4 trial: ~two-thirds of lost weight regained within one year of stopping). Most clinical guidelines recommend ongoing treatment as long as it remains effective and tolerated, similar to how blood pressure or cholesterol medications are taken long-term.

Yes. The SELECT trial (2023) enrolled 17,604 adults with obesity and established cardiovascular disease (no diabetes) and found that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) by 20% over approximately 34 months. This was the first trial to show cardiovascular benefit for a weight-loss drug in this population. See SELECT trial →

The STEP (Semaglutide Treatment Effect in People with Obesity) programme comprises 8 phase 3 trials evaluating semaglutide 2.4 mg for weight management across different populations: adults without diabetes (STEP 1), adults with type 2 diabetes (STEP 2), intensive behavioural therapy add-on (STEP 3), long-term maintenance (STEP 4), sustained weight loss (STEP 5), and others. The trials established the 14.9% average weight loss benchmark. See STEP trial evidence →

The SELECT trial (2023, NEJM) was a landmark cardiovascular outcomes trial of semaglutide 2.4 mg in 17,604 adults with obesity (BMI ≥27) and pre-existing cardiovascular disease but without diabetes. After a mean follow-up of 34 months, semaglutide reduced MACE by 20% vs placebo (6.5% vs 8.0%). This was the first evidence that weight-loss treatment directly reduces cardiovascular mortality in this population. See SELECT trial →

Direct Indian-specific semaglutide RCT data is limited, but pooled analyses from STEP trials including South Asian participants, ICMR-INDIAB epidemiological data, and ESI India guidelines all support efficacy and safety in Indian patients. The Indian obesity phenotype (higher visceral fat at lower BMI) may mean clinical benefits appear at lower body weights than in Western trials. See Indian evidence →

Semaglutide is a GLP-1 receptor agonist only. Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial showed tirzepatide 15 mg produced approximately 22% mean weight loss versus semaglutide's ~15% in STEP 1. Tirzepatide is not yet approved in India as of early 2026. Head-to-head comparisons (SURMOUNT-5) suggest tirzepatide produces greater weight loss, but semaglutide has the longer safety track record and is currently the available option in India.